This post was just published on ZYX Buy Change Alert. In our divided country there are very few things on which Republicans and Democrats, liberals and conservatives agree. One of those very few things is that drug prices are too high. It makes no sense for Americans to often pay ten times
Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside politics and viewing the plan neutrally, two things jump out. First, the House Republicans’ plan keeps the basic framework of Obamacare. No wonder some are calling it “Obamacare Lite.”
This post was just published on ZYX Buy Change Alert. On February 1st we issued a call to take profits on MNTA. Depending upon how you traded, your profits would have been 74%. We got out at the top. Now the stock has fallen providing an opportunity to enter again. The buy
Donald Trump is starting his first full week as U.S. president. Bearish investors have been out in full force, proclaiming, with high confidence, that it’s time to sell stocks. At the same time, bullish gurus are saying just the opposite. So who’s right? Let’s explore the answer. First, we need
Donald Trump knocked yet another industry in his press conference Wednesday, but this time it wasn’t manufacturers or car makers. It was health care. And shares of U.S. pharmaceutical companies promptly fell, dropping by an average range of about 3% to 5%. “We’ve got to get our drug industry back,”
I can safely say that, from my 35 years in the financial markets, to be consistently successful at investing, one must put prudence over popularity. Human nature as it is, investors often find it difficult to take unpopular actions. My motivation in writing this column is to nudge you
Only three days ago I predicted that a performance chase is on. Wednesday’s nearly 300-point move in the Dow Jones Industrial Average shows the prediction was spot on. A performance chase buy program triggered the rally and performance chase turned the rally into a buying panic. This was yesterday; now
Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely to succeed. Obamacare in its current form is the walking dead. Trump has said that he will replace Obamacare with something better. In his speeches, Trump outlined certain key points
This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide
This post was just published on ZYX Buy Change Alert. MDVN is the 113th company in our portfolio involved in M&A. The Arora Report’s unrivaled performance in picking companies that get bought out continues. Congratulations to those holding MDVN. MDVN has received an $81.50 cash buyout offer from PFE. MDVN is long